Streetbeat News

CELZ

Creative Medical Technology Holdings, Inc.

https://www.creativemedicaltechnology.com

Industry

Biotechnology

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Open

3.15

Mkt cap

3.7M

Volume

71K

High

3.23

P/E Ratio

-0.69

52-wk high

10.28

Low

2.65

Div yield

N/A

52-wk low

2.65

Creative Medical Technology Holdings' shares surged following the FDA's authorization for expanded access therapy using CELZ-20, indicating a positive development for the company and its stakeholders.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 3:42 pm

A correction has been issued stating that Creative Medical Technology (CELZ) has not filed any new patent applications, contrary to previous reports.

Portfolio Pulse from Charles Gross

March 07, 2024 | 3:04 pm

Trading of Creative Medical Technology Holdings, Inc. (CELZ) shares has resumed after a temporary halt. This development is crucial for investors monitoring the stock's performance.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 2:58 pm

Creative Medical Technologies has filed four new patent applications covering a range of medical treatments using regenerative cells and adjuvants. These applications focus on reproductive failure, orthopox viruses, space travel-associated bone density loss, and hair loss prevention and treatment.

Portfolio Pulse from Charles Gross

March 07, 2024 | 2:49 pm

Trading of Creative Medical Technology Holdings, Inc. (CELZ) shares was resumed but was halted again due to a circuit breaker trigger. This indicates significant volatility in the stock.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 2:45 pm

Shares of Creative Medical Technology (CELZ) were halted on a circuit breaker after surging 85%. This significant price movement triggered the halt to ensure market stability and fairness.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 2:35 pm

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) announced FDA authorization for CELZ-201, a cell-based therapy aimed at preventing Type 1 Diabetes Mellitus (T1D) in high-risk individuals. This marks a significant advancement in T1D prevention, showcasing CELZ's commitment to innovative healthcare solutions.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 2:23 pm

In Wednesday's after-market session, several healthcare stocks showed significant movement. SCWorx (WORX) led the gainers with a 60.8% increase, while Nexalin Technology (NXL) experienced the largest drop among the losers, falling 14.4%. Notable mentions include IO Biotech (IOBT) and Vicarious Surgical (RBOT), which released their Q4 earnings recently, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 9:31 pm

CrowdStrike Holdings (CRWD) shares surged 27% after reporting better-than-expected Q4 earnings and revenues, with positive guidance for Q1 and FY25, leading to raised price targets by analysts. Creative Medical Technology Holdings, Inc. (CELZ) saw an 85% increase after receiving FDA Orphan Drug Designation for CELZ-101. TRxADE Health, Inc. (MEDS) announced a special cash dividend of $8/share, resulting in a 67% stock price increase.

Portfolio Pulse from ryanfaloona@benzinga.com

March 06, 2024 | 1:33 pm

In Wednesday's pre-market session, several healthcare stocks showed significant movement. NKGen Biotech, Creative Medical Tech, and Vincerx Pharma were among the top gainers, with NKGen Biotech leading at a 69.4% increase. On the downside, Heart Test Laboratories, Jaguar Health, and BeyondSpring were the major losers, with Heart Test Laboratories experiencing the largest drop of 17.6%. TRACON Pharma's stock also rose following their Q4 earnings report.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 1:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.